Carnegie acted as joint global co-ordinator and joint bookrunner in the directed share issue of 2,000,000 new shares at a subscription price of SEK 545 per share.
Camurus is a Swedish science-led pharmaceutical company committed to developing and commercializing innovative and long-acting medicines for the treatment of severe and chronic diseases.